It markedly improved outcomes, including in high-risk CLL with del(17p) or TP53 mutations, and demonstrated strong efficacy in other B-cell malignancies such as Waldenström macroglobulinemia, with response rates approaching 90% [8-10], and marginal zone lymphoma (MZL) [11]. This evidence concerns the gene TP53 and marginal zone lymphoma.